Prof. Marek Trněný: Highlights of Mantle Cell Lymphoma - ICML 2017
Prof. Marek Trněný on his research on mantle cell lymphoma
Progress in mantle cell lymphoma over the last 15 years
Message to mantle cell lymphoma physicians and patients
SPRINT trial: Lenalidomide for relapsed/refractory mantle cell lymphoma
ASH 2014: Phase II SPRINT study of lenalidomide in relapsed/refractory mantle cell lymphoma
Rituximab maintenance key to outcome improvement in mantle cell lymphoma
Mantle cell lymphoma advances (Part 1)
Treating mantle cell lymphoma earlier in the disease course
iwNHL 2017 highlights: the PDX model
Prof. Marek Trněný discusses highlights from 13-ICML 2015
Prof John Gribben and Prof Marek Trněný at ASH 2014: Mantle cell lymphoma advances (Part 1)
Prof John Gribben and Prof Marek Trněný at ASH 2014: Mantle cell lymphoma advances (Part 2)
Dr. Eskelund on Study of TP53 Mutations in Mantle Cell Lymphoma
Meet Prof. Marek Trněný of Charles University in Prague, Czech Republic
ASH 2014: Highlights in mantle cell lymphoma
Mantle Cell Lymphoma: Evolution of Therapy
Phase II study of Lenalidomide Vs Best Investigator’s in Choice Relapsed/Refractory MCL
Prof. Marek Trněný: DLBCL patients superior ≥ 80y treated with anthracycline-based chemotherapy
